ArticleFrontiers in medicine2026
Systemic lupus erythematosus complicated by refractory
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with systemic lupus erythematosus (SLE) receiving long-term glucocorticoids and immunosuppressants are at markedly increased risk of opportunistic infections. Case presentation: We report a 52-year-old female with SLE on long-term prednisone, azathioprine, leflunomide, and hydroxychloroquine, who developed bilateral tibial and femoral osteomyelitis complicated by soft tissue abscesses, drug-induced dermatitis, and severe malnutrition. Conventional microbiological tests remained negative. Metagenomic next-generation sequencing (mNGS) of lower-extremity secretions and pus identified MAC. She underwent five surgical debridements and prolonged multidrug antimycobacterial therapy (azithromycin, rifampicin, ethambutol, amikacin), along with nutritional support and immunosuppressant adjustment. The infection was controlled with no SLE flare, and she recovered favorably. Conclusion: Disseminated MAC osteomyelitis can occur in SLE patients under sustained immunosuppression even during disease remission. mNGS enables rapid pathogen identification and is crucial for diagnosing complicated infections. Management requires combined surgical debridement, prolonged antimycobacterial therapy, and multidisciplinary care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.